Antineoplastics (BRAF inhibitors)
- Target activating BRAF mutations
- Melanoma is the classic use
- Often pair with MEK inhibitor
- reduces paradoxical MAPK activation
- Fever/rash/arthralgia vary by regimen
- Secondary skin tumors occur with BRAF alone
- Mutation confirmation is essential
Class at a glance
- Target activating BRAF mutations
Pharmacology
- Often pair with MEK inhibitor
- reduces paradoxical MAPK activation
Clinical role
- Melanoma is the classic use
- Secondary skin tumors occur with BRAF alone
- Mutation confirmation is essential
Safety / monitoring
- Fever/rash/arthralgia vary by regimen
Self-check
- Which inhibitor is often paired with a BRAF inhibitor?
A MEK inhibitor. - What must be confirmed before BRAF-targeted therapy?
The mutation.
Drugs in this class (2)
All drug classes · Open Antineoplastics (BRAF inhibitors) in the interactive console ↗